Day: August 9, 2022

Consolidated net revenue increased by 48% year-over-year to $23.1 million in Q2 2022 Israel net revenue increased by 212% year-over-year to $7.2 million in Q2 2022 Announced achievement of THCV equity milestone TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announces its 2022 second quarter business results. “I am encouraged by the progress we are making to realign our business around our brands to become more efficient in our decision making and agile throughout our supply chain,” said Mike Gorenstein, Chairman, President and CEO, Cronos. “Our supply chain transformation in Canada is going very well, with GrowCo achieving profitability in the year-to-date period, and the operational efficiencies we envisioned when we embarked on this initiative are starting...

Positive Results in Two Phase 2 Trials of EscharEx FDA Assigned PDUFA Target Date of January 1, 2023 for NexoBrid BLA Enhanced the Board and Leadership Team Conference Call Begins Today at 8:30 AM Eastern Time YAVNE, Israel, Aug. 09, 2022 (GLOBE NEWSWIRE) — MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced financial results for the second quarter ending June 30, 2022. Second Quarter Highlights and Recent Developments:Enhanced the Company’s Board and executive leadership team with the appointments of Nachum (Homi) Shamir as Chairman of the Board of Directors, Ofer Gonen as Chief Executive Officer, Tzvi Palash as Chief Operating Officer and Dr. Robert J. Snyder as Chief Medical Officer.Announced positive...

– SNS-101 pre-IND feedback received from FDA with program on track for IND filing in first half of 2023 – – New SNS-101 single dose pharmacokinetic data in non-human primates to be presented in the third quarter of 2022 – – On track with SNS-102 candidate selection, including generation of pH-sensitive parental antibodies – – Strong balance sheet with cash runway into the first quarter of 2025 – BOSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today reported financial results for the second quarter ended June 30, 2022 and provided recent business updates. “This has been a productive and rewarding time as we progress our TMAb™ platform...

Total revenues for the second quarter 2022 were $55.6 million, compared to $20.0 million for the same period in 2021, representing a 178% increase CAPLYTA net product revenues for the second quarter 2022 were $55.1 million, representing a 190% increase over the same period in 2021 and a 58% increase over the first quarter 2022 Second quarter 2022 CAPLYTA new and total prescriptions increased 225% and 191%, respectively, versus the same period in 2021 Second quarter 2022 CAPLYTA new and total prescriptions increased 55% and 51%, respectively, versus the first quarter 2022 NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results...

TORONTO, Aug. 09, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three and six-month period ended June 30, 2022. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Recent HighlightsTotal Natesto® prescriptions in the US rose 47% year-over-year in the second quarter of 2022 and were up approximately 23% sequentially over the fiscal 2022 first quarter The Company continues to finalize preparations for the re-launch of Noctiva™ in the US, now anticipated to take place by the first quarter of 2023 The rollout of Natesto® remains on track, underscored by focused execution of the Company’s growth strategy in the US During the second...

XTX101, tumor-selective anti-CTLA-4, has successfully reached dose levels exceeding the target dose with limited active (unmasked) molecule in the periphery in ongoing Phase 1 clinical trial XTX202, tumor-selective IL-2, advancing in dose-escalation of Phase 1 clinical trial Investigational new drug application planned for XTX301, tumor selective IL-12, in fourth quarter of 2022 Uli Bialucha, Ph.D., promoted to Chief Scientific Officer and Chris Frankenfield promoted to Chief Legal and Administrative Officer Strong financial position with $159.4 million in cash and cash equivalents as of June 30, 2022 expected to provide cash runway into first half of 2024; multiple data milestones anticipated for XTX101 and XTX202 in 2023 WALTHAM, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company...

Company Takes Delivery of Norwegian Prima, the First of Six Innovative Ships in the Ground-Breaking Prima Class Operating Cash Flow Positive for the Quarter Go-to-Market Strategy Continues to Drive Robust Pricing Company Focused on Laying Foundation for Record Year in 2023 MIAMI, Aug. 09, 2022 (GLOBE NEWSWIRE) — Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd., “Norwegian Cruise Line Holdings”, “Norwegian” or the “Company”) today reported financial results for the second quarter ended June 30, 2022 and provided a business update. “We are encouraged by the continued strong consumer demand we are experiencing which is reflected in our record pricing, accelerating booking volumes, especially for 2023 and beyond, and highest ever onboard revenue generation. Having emerged from the pandemic and...

Financial HighlightsSolid Underlying Streaming Growth Despite Ad-Supported Pressure Impressive Recovery of Artist Services with Continued Double-Digit Revenue Growth Continued Momentum in Music Publishing with Double-Digit Revenue Growth Significant Growth in Operating and Free Cash FlowFor the three months ended June 30, 2022Total revenue grew 7% or 12% in constant currency Digital revenue grew 2% or 6% in constant currency Net income was $125 million versus $61 million in the prior-year quarter OIBDA decreased 3% to $233 million versus $241 million in the prior-year quarter or increased 3% in constant currency Adjusted OIBDA decreased 3% to $255 million versus $263 million in the prior-year quarter or increased 2% in constant currency Adjusted EBITDA decreased 7% to $263 million versus $282 million in the prior-year quarter Cash...

8.5% constant currency revenue growth, supported by strong performance across both segments with price actions and volume gains CHICAGO, Aug. 09, 2022 (GLOBE NEWSWIRE) — Whole Earth Brands, Inc. (the “Company” or “we” or “our”) (Nasdaq: FREE), a global food company enabling healthier lifestyles through premium plant-based sweeteners, flavor enhancers and other foods, today announced its financial results for its second quarter ended June 30, 2022. The Company also reaffirmed fiscal year 2022 guidance. Second Quarter HighlightsReported consolidated revenue growth of 5.5%, or 8.5% on a constant currency basis Branded CPG constant currency revenue growth of 8.1% compared to 2021 Flavors & Ingredients constant currency revenue growth of 9.9% compared to 2021 Operating income of $7.7 million and adjusted EBITDA of $19.7 millionAlbert...